Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in 131I-refractory differentiated thyroid cancer
NCT02731352Phase 2Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2016
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in differentiated thyroid cancer (DTC), sponsored by Peking Union Medical College Hospital. Started Mar 2016; status: completed.
02
Drugs
Rivoceranib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT02731352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02731352.